logo-loader
viewPreveCeutical Medical Inc

PreveCeutical results show key peptides derived from blue scorpion venom could reduce the aggressive nature of brain cancer

Preliminary screening in an aggressive brain cancer assay successfully identified four lead peptides that inhibit the activity of a target protein that is found in the progression in certain glioblastomas

hand pointing at brain scans
Peptides may slow down the invasive spread of brain cancer cells

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) is seeing encouraging preliminary results from its research and development program that is expected to enable the company to generate key Nature Identical™ peptide therapeutics for use in treatments of brain cancer.

The health sciences company is engaged in a study that uses blue scorpion venom-derived peptides to better understand its therapeutic application in cell-based brain cancer models.

READ: PreveCeutical Medical reports successful preliminary screening of key peptides from scorpion venom research program

Preliminary screening in an aggressive brain cancer assay successfully identified four lead peptides that inhibit the activity of a target protein that is found in the progression in certain glioblastomas.

Further screening highlighted the peptide’s ability to inhibit the invasion of glioblastoma cells — an important development given the invasive nature of the cells is a key factor in the aggressive spread of the disease and resulting in poor prognosis.

Research ongoing

The Vancouver-based company said in a statement that although this facet of the screening process is nearing completion, the peptide program is ongoing. According to PreveCeutical, the results have helped to progress the company towards assessing the efficacy of the lead peptides in more sophisticated glioblastoma (brain cancer) research.

PreveCeutical currently has five research and development programs underway, including gene therapy for diabetes and obesity, non-addictive analgesic peptides to replace fentanyl and the like, and soluble drug delivery program, among others.

Shares of PreveCeutical were trading at C$0.07 in Canada and US$0.05 in the US on Wednesday.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: PreveCeutical Medical Inc

Price: 0.02 CAD

CSE:PREV
Market: CSE
Market Cap: $7.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc named herein, including the promotion by the Company of PreveCeutical Medical Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

PreveCeutical prepares for the final stage of their Sol-Gel program

PreveCeutical (CNSX:PREV) Chief Research Officer Dr Harry Parekh joined Steve Darling from Proactive Investors Vancouver to talk about the companies progress in the development of their sol-gel. Parekh telling proactive the next step they are undertaking with human tissue. He also talked...

on 27/4/19

2 min read